Green Cross' GCFlu Quadrivalent approved to protect against four influenza strains in South Korea

Nov 26 2015

Green Cross Corporation (Green Cross), a South Korean biopharmaceutical company, announced today that South Korea's Ministry of Food and Drug Safety has approved GCFLU QUADRIVALENT (Influenza Virus Vaccine) for immunisation of adults to help prevent disease caused by seasonal influenza (flu) virus subtype A and B. GCFlu Quadrivalent is the first locally-manufactured vaccine to cover against four influenza strains.

Until recent years, seasonal flu vaccines included two A virus strains and only one B strain. GCFlu Quadrivalent adds coverage a second B strain to help protect against flu disease.

"Green Cross is committed to providing new immunization option for the protection of flu, and we are excited to introduce GCFlu Quadrivalent as an important newest addition to the GCFlu which is administered to more than 100 million people in the world last 5 years," said EC Huh, Ph. D., President of Green Cross Corporation.

GCFlu Quadrivalent will be available to the healthcare providers in South Korea for the 2016-2017 flu season in prefilled syringes for intramuscular administration.